Clinical Research Directory
Browse clinical research sites, groups, and studies.
Switching to E-cigarettes in Smokers Not Interested in Quitting
Sponsor: University of Kansas Medical Center
Summary
The objectives of this application are to 1) compare short- and long-term harm reduction and abuse liability potential of a nicotine salt pod-based electronic cigarettes (EC) in adult (AA) exclusive EC, dual cig-EC, and exclusive cig users, 2) characterize factors that predict who switches fully, partially, or not at all, and 3) examine if harm reduction can be further enhanced by treating dual users with varenicline (VAR) to eliminate cigarette smoking.
Official title: 4th Generation E-cigarettes: Reducing Harm and Quitting Combustible Cigarettes in Dual Users
Key Details
Gender
All
Age Range
21 Years - Any
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2023-07-17
Completion Date
2027-02-28
Last Updated
2025-12-29
Healthy Volunteers
Yes
Conditions
Interventions
Varenicline Tartrate
0.5 mg once daily for days 1-3, 0.5mg twice daily for days 4-7 and 1.0 mg twice daily from day 8 through week 12.
Placebo
One pill (white) once daily for days 1-3, one pill (white) twice daily for days 4-7 and one pill (blue) twice daily from day 8 through week 12.
Electronic cigarette
Nicotine salt pod based e-cigarette in 5% nicotine
Locations (2)
Swope Health Central
Kansas City, Missouri, United States
University of Kansas Medical Center
Kansas City, Missouri, United States